Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
You may also be interested in...
Neurocrine Resubmits Immediate-Release Indiplon
Sleep aid could at last reach market late in 2008.
Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.
FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.